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BMS-488043 is a novel and unique oral small-molecule inhibitor of the attachment of human immu-
nodeficiency virus type 1 (HIV-1) to CD4 lymphocytes. The antiviral activity, pharmacokinetics, viral
susceptibility, and safety of BMS-488043 were evaluated in an 8-day monotherapy trial. Thirty HIV-1-
infected study subjects were randomly assigned to sequential, safety-guided dose panels of 800 and 1,800
mg BMS-488043 or a matched placebo in a 4:1 ratio, and the drug was administered every 12 h with a
high-fat meal for 7 days and on the morning of day 8. Dose-related, albeit less-than-dose-proportional,
increases in plasma BMS-488043 concentrations were observed. Mean plasma HIV-1 RNA decreases from
the baseline for the BMS-488043 800- and 1,800-mg dose groups on day 8 were 0.72 and 0.96 log10
copies/ml, respectively, compared with 0.02 log10 copies/ml for the placebo group. A lower baseline
BMS-488043 50% effective concentration (EC50) in the active-treatment groups was predictive of a greater
antiviral response. Although absolute drug exposure was not associated with an antiviral response, the
trough concentration (Ctrough), adjusted by the baseline EC50 (Ctrough/EC50), was associated with antiviral
activity. During dosing, four subjects experienced >10-fold reductions in viral susceptibility to BMS-
488043, providing further support of the direct antiviral mechanism of BMS-488043. BMS-488043 was
generally safe and well tolerated. These results suggest that further development of this novel class of oral
HIV-1 attachment inhibitors is warranted.
There is a continuing need for new classes of antiretroviral
drugs, driven by increasing concerns over human immunode-
ficiency virus type 1 (HIV-1) resistance to existing medications,
the requirement for lifelong antiretroviral therapy for HIV-1-
infected individuals, and the goal of minimizing toxicity (2, 3).
The process of HIV-1 entry into host cells offers considerable
potential for therapeutic intervention, with viral entry proceed-
ing through multiple sequential steps involving attachment,
coreceptor binding, and fusion (8, 13). The early step of viral
entry into the host cell is accomplished through binding of the
viral envelope glycoprotein complex gp160 to the cellular re-
ceptor, CD4. This attachment is followed by conformational
changes of the gp160 external glycoprotein portion, gp120,
which facilitates the second step involving binding to a cellular
coreceptor, usually the chemokine receptor CCR5 or CXCR4.
Coreceptor binding, in turn, facilitates a large conformational
change and initiates the final entry event involving the gp160
transmembrane glycoprotein gp41, which mediates the fusion
of viral and host cell membranes (8, 13).
There are two compounds representing two classes of entry
inhibitors currently approved for clinical use, maraviroc, a
CCR5 antagonist that targets coreceptor binding, and enfu-
virtide, an injectable peptide that inhibits the final step of
membrane fusion (1, 8). While they are effective, the use of
these existing classes has been limited. The need for laborious
and expensive tropism testing and the concern over selecting
CXCR4-tropic virus have impacted maraviroc use (2), while
the inconvenient route of administration, related injection site
side effects, and the availability of more convenient options
have severely limited the use of enfuvirtide (12). HIV-1 attach-
ment inhibitors are a new class of selective small-molecule
inhibitors of HIV-1 that bind specifically to gp120 and block
attachment to CD4 lymphocytes (5, 10). Unlike the activity of
CCR5 antagonists, that of attachment inhibitors is indepen-
dent of human chemokine coreceptor binding and persists
irrespective of viral tropism or the host cell phenotype (5, 7,
10). Furthermore, since attachment inhibitors target a viral
protein rather than a host chemokine receptor, they are not
expected to impact human immune responses.
The development of BMS-378806, a prototype attachment
inhibitor, established gp120 as a viable target for small-mole-
cule inhibitors (5). This compound exhibited some favorable
pharmacokinetic traits, such as low protein binding, good oral
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bioavailability in animal models, and a good safety profile, in
preclinical testing (10). However, the compound had less-than-
optimal pharmacokinetic characteristics overall, such as a short
half-life (t1/2) (16), which suggested that the drug would not
achieve target exposures in humans at acceptable doses and
intervals. BMS-488043 is a related compound with improved in
vitro antiviral activity and a longer t1/2 than BMS-378806 in
preclinical studies (11, 14, 17). BMS-488043 exhibits potent
antiviral activity against macrophage-, T-cell-, and dual-tropic
HIV-1 laboratory strains (B subtype) and potent antiviral ac-
tivity against a majority of subtype B and C clinical isolates,
with median 50% effective concentrations (EC50) of 36.5 and
61.5 nmol/liter, respectively (11). Data from a limited number
of clinical isolates showed that BMS-488043 exhibited a wide
range of activity against the A, D, F, and G subtypes, with no
activity observed against three subtype AE isolates (11). The
safety, tolerability, and pharmacokinetics of BMS-488043 were
previously evaluated in two placebo-controlled studies with
healthy non-HIV-infected adults (6). BMS-488043 was gener-
ally safe and well tolerated, with no serious adverse events
(AEs) in single- and multiple-dose studies. Systemic exposure
from repeat dosing was generally dose proportional (400 to
1,200 mg with a high-fat meal and 400 to 800 mg with a light
meal), with a limited increase in exposure at higher doses.
Based on the findings in healthy adults, a dose of 800 mg twice
daily with a high-fat meal was expected to provide minimum
concentrations adequate to suppress HIV-1 isolates.
In this 8-day monotherapy trial, the antiviral activity, phar-
macokinetics, and safety of BMS-488043 were evaluated in
HIV-1-infected subjects. We also evaluated viral susceptibility
to BMS-488043 and blood levels of BMS-488043 as predictors
of antiviral activity and assessed the development of resistance
to BMS-488043 during dosing.
(Part of this research was presented as an abstract at the
11th Conference on Retroviruses and Opportunistic Infec-
tions, 8 to 11 February 2004, San Francisco, CA.)
MATERIALS AND METHODS
Study design and patients. This was a randomized, double-blind, placebo-
controlled, sequential, ascending multiple-dose study conducted with HIV-1-
infected subjects. We randomly assigned 15 subjects to each of two sequential
dose panels of 800 and 1,800 mg BMS-488043 (Bristol-Myers Squibb, Princeton,
NJ) provided as 200-mg BMS-488043 capsules or a matched placebo in a 4:1
ratio, with treatment administered orally every 12 h with a high-fat meal (945
kcal, 55 g fat) on days 1 to 7 and on the morning of day 8. Subjects were not
enrolled for the 1,800-mg dose until safety data evaluated through day 8 for at
least 10 subjects confirmed the safety and tolerability of the 800-mg dose. There
was no intrasubject dose escalation. The study was conducted in accordance with
Good Clinical Practice and the ethical principles of the Declaration of Helsinki.
The protocol was approved by the institutional review board at each study site.
All subjects provided written informed consent prior to participation in the study.
Eligible subjects were HIV-1-infected male or female adults at least 18 years
of age with a CD4 T-cell count of at least 250 cells/l and a plasma HIV-1 RNA
level of 5,000 to 500,000 copies/ml (Roche Amplicor Assay, version 1.5) within 12
weeks prior to and at the time of a screening visit. Subjects did not receive
antiretroviral therapy for at least 16 weeks prior to study participation and were
otherwise medically stable as determined by physical, 12-lead electrocardiogram
(ECG), and laboratory examinations. Women with childbearing potential were
required to have a negative serum or urine pregnancy test within 24 h prior to
taking the study medication. Prohibited therapies included the use of any agent
known to affect hepatic metabolism or compete with BMS-488043 for CYP3A4
metabolism, the use of any agent known to affect gastrointestinal motility within
1 week of enrollment, and the use of any other drug or herbal preparation within
1 week of enrollment unless approved by the investigator and the study medical
monitor.
Evaluations. Physical examination, vital signs, 12-lead ECG, clinical laboratory
testing, urine drug screening, pregnancy testing for women, and blood sampling
for HIV-1 RNA analysis and CD4 and CD8 T-cell counts were conducted at
screening (within 30 days prior to study enrollment) and at selected time points
throughout the study. Blood samples were taken before entry on days 3 to 1
and prior to dosing on days 1 to 8 for plasma HIV-1 RNA analysis. In addition,
blood samples taken on days 1 and 8 were used for CD4/CD8 analyses and to
examine viral susceptibility to BMS-488043. Viral drug susceptibility was mea-
sured as the EC50 of the drug, as described below. Plasma samples for pharma-
cokinetic assessments were taken before dose administration on days 1 to 8 and
also at 1, 2, 3, 4, 6, 8, and 12 h after dose administration on days 1 and 8. During
a posttreatment follow-up from day 9 to day 14, subjects had additional blood
samples taken for HIV-1 RNA, pharmacokinetic, and CD4/CD8 analyses. AE
monitoring was conducted from the first dose administration to study discharge,
and monitoring for serious AEs (SAEs) was continued until 30 days after study
discharge.
Pharmacokinetic analyses. Blood samples were collected by indwelling cath-
eter or direct venipuncture into tripotassium EDTA-coated tubes from which
plasma samples were prepared within 60 min of collection and stored at or below
20°C until ready for analysis. Approximately 350 ml of blood was drawn from
each subject during the study. Plasma samples were analyzed at a single central
site (Charles River Laboratories, Worcester, MA) using a validated liquid chro-
matography-mass spectrometry method for BMS-488043 concentrations (4). All
samples from any given subject were analyzed in a single run. The standard
curves were well fitted by a 1/x-weighted quadratic equation over a concentration
range of 1.00 to 1,000 ng/ml and were used to define the quantifiable limits for
study samples. Estimates of within-run and between-run assay variabilities for
quality control samples were calculated using one-way analysis of variance, and
the coefficient of variation (CV) was no greater than 13.9%, with deviation from
the nominal concentrations of no more than 7.4%. The plasma concentration-
time data for BMS-488043 were analyzed by noncompartmental methods (Ki-
netica, version 4.2; Thermo Electron Corporation, Philadelphia, PA) and were
based on experimental observations of the peak plasma concentration (Cmax),
the time to Cmax (Tmax), and the trough plasma drug concentration measured
predose in the morning (Ctrough). The area under the plasma concentration-time
curve over one dosing interval (12 h) [AUC(TAU)] was calculated using the mixed
log-linear trapezoidal method. The geometric mean of the Ctrough values col-
lected on days 6 to 8 was calculated and used as the estimate of Ctrough at steady
state (Ctrough D6-8). The accumulation index (AI) was defined as the ratio of
AUC(TAU) at steady state to AUC(TAU) after the first dose.
Drug susceptibility analyses. Drug susceptibility was determined using a cell
fusion assay as a measure of HIV-1 envelope susceptibility to attachment inhib-
itors. HIV-1 RNA was isolated from peripheral blood mononuclear cells from
study subjects, and the env genes were amplified using published procedures (9).
The PCR products were used to directly express the envelope protein using the
TOPO expression kit (Invitrogen, Carlsbad, CA). The HIV-1 envelope-mediated
fusion assay was performed using two populations of HeLa cells designated
effector and target cells. The effector cells were prepared by cotransfecting 1.7 
106 cells with 3 g of linear envelope expression element and 3 g of pTET-Off
plasmid (BD Biosciences Pharmingen, San Diego, CA) using a Lipofectamine
Plus kit (Invitrogen). After 4 h, the transfection mixture was removed, replaced
with culture medium, and incubated overnight. HeLa cells expressing CD4,
CXCR4, and CCR5 and containing an integrated copy of an inducible luciferase
reporter gene were used as target cells (10). The effector and target cells were
trypsinized, mixed at a ratio of 1:2, and seeded into a 96-well plate at 5  104/well
in the presence of various concentrations of the test compound. After 12 to 18 h
of incubation, luciferase activity was determined using a Steady-Glo Luciferase
Assay System (Promega Corp., Madison, WI) and the EC50 was determined.
In vitro EC50s were adjusted for protein binding prior to inclusion in the
statistical analysis data sets. The protein binding-adjusted (PBA) EC50s were
computed by the following formula: PBA EC50 (ng/ml)  EC50 (nmol/liter) 
1/(1  0.95)  molecular weight of BMS-488043 (422.43)/1,000.
Statistical analyses. The primary assessment in the study was antiviral activity
following 7.5 days of dosing of BMS-488043 as measured by the change in log10
HIV-1 RNA from the baseline to day 8 and the maximum decline in log10 HIV-1
RNA during the study period. A sample size of 12 subjects receiving a specified
dose of BMS-488043 was calculated to provide 90% power to detect a decrease
of 0.7 from the baseline in the mean log10 HIV-1 RNA level by day 8. The
baseline was defined as the predose value on day 1 for all variables except log10
HIV-1 RNA, where the baseline was defined as the mean log10 HIV-1 RNA
values before entry and predosing on day 1. Changes in log10 HIV-1 RNA from
VOL. 55, 2011 STUDY OF ORAL HIV-1 ATTACHMENT INHIBITOR 723
the baseline were summarized by treatment and study day. The maximum decline
from the baseline in log10 HIV-1 RNA levels over the entire study period was
determined for each subject and summarized by treatment. Summary statistics
for changes from the baseline in CD4 and CD8 T-cell counts were derived by
treatment and study day. Summary statistics for pharmacokinetic parameters of
BMS-488043 were tabulated by dose and study day. The association between the
baseline susceptibility to BMS-488043 and antiviral activity was explored by
scatter plots showing PBA EC50s versus the observed change in log10 HIV-1
RNA from the baseline to day 8. The relationship was estimated using linear
regression. The corresponding analysis was also performed for the maximum
decline in log10 HIV-1 RNA from the baseline. The associations between phar-
macokinetic measures of exposure to BMS-488043 and antiviral activity and
between the ratio of drug exposure to the baseline viral susceptibility and anti-
viral activity were explored. Day 8 pharmacokinetic parameters, specifically,
AUC(TAU), Cmax, Ctrough, and Ctrough D6-8, were used as measures of exposure to
BMS-488043, and the ratio of drug exposure to the baseline viral susceptibility
was defined by the pharmacokinetic parameter divided by the baseline PBA
EC50. Change in viral susceptibility was assessed using the ratio of the EC50 of
BMS-488043 on day 8 to that on day 1. All AEs recorded during the study were
listed and tabulated by treatment, body system, and primary term. Vital signs and
clinical laboratory test results were listed and summarized by treatment. Any
significant physical examination findings and clinical laboratory results were
listed. ECG recordings were evaluated by the investigator, and abnormalities, if
present, were listed. Statistical analyses were performed using SAS/STAT Ver-
sion 8.2 software (SAS Institute, Inc., Cary, NC).
RESULTS
Subject disposition and baseline characteristics. A total of
30 subjects were enrolled. All subjects completed treatment,
with no doses missed and no subject discontinuing. Twelve
subjects at each dose received BMS-488043, and three subjects
at each dose received the placebo. The baseline characteristics
of age, sex, race, and height were equally distributed among
the treatment groups and BMS-488043 dose panels (Table 1);
however, weight and body mass index appeared to be lower in
the 800-mg dose group than in the 1,800-mg dose group and
the placebo group. A higher percentage of subjects in the
1,800-mg dose group (67%) were antiretroviral treatment
naïve than in the 800-mg dose group (42%) and the placebo
group (50%). At the baseline, the mean HIV-1 RNA level was
4.55 log10 copies/ml and the median CD4
 T-cell count was
368 cells/l (Table 1).
Antiviral activity. The mean change from the baseline in the
log10 HIV-1 RNA level over time is shown in Fig. 1. Compared
with the placebo, the plasma HIV-1 RNA level decreased from
the baseline in a dose-dependent manner in subjects who re-
ceived either the 800- or the 1,800-mg BMS-488043 dose. The
mean HIV-1 RNA level decreases from the baseline ( the
standard deviation) for the BMS-488043 800- and 1,800-mg
dose groups on day 8 were 0.72 ( 0.51) and 0.96 ( 0.63)
log10 copies/ml, respectively, compared with 0.02 ( 0.26) log10
copies/ml for the placebo group. The median maximum de-
creases in HIV-1 RNA from the baseline over the study period
were 1.15 and 1.32 log10 copies/ml for the BMS-488043 800-
and 1,800-mg dose groups, respectively, compared with 0.2
log10 copies/ml for the placebo group. Following initiation of
treatment, plasma HIV-1 RNA continued to decline until ap-
proximately day 9 or for 1 day after the last dose of study
medication. There were no remarkable differences in CD4 or
CD8 T-cell counts between treatment groups (data not
shown).
Pharmacokinetics. Following oral administration of a single
dose of BMS-488043 or following twice-daily oral administra-
tion for 7.5 days, there were dose-related increases in the
plasma BMS-488043 concentration for both the 800- and
1,800-mg doses (Table 2). These dose-related increases in the
plasma BMS-488043 concentration were less than dose pro-
portional. The Cmax was reached around 4 h after dosing on
both day 1 and day 8, with minimal accumulation of BMS-
488043 (AI of 1.0 to 1.3) noted following multiple dose admin-
istrations, despite estimated half-lives of 15 to 17.7 h. Summary
statistics of pharmacokinetic parameters are shown in Table 2.
Predictors of antiviral activity. The relationships between
antiviral activity (represented by changes in the plasma HIV-1
RNA level from the baseline in log10 copies/ml following dos-
ing with BMS-488043) and both viral susceptibility (as mea-
sured by in vitro PBA EC50 on day 1) and BMS-488043 phar-
macokinetics were explored.
The baseline susceptibility to BMS-488043 showed a wide
range of individual variability, with PBA EC50s ranging from
27.71 to more than 1,000,000 ng/ml in the 800-mg dose group
and from 5.83 to 6,868 ng/ml in the 1,800-mg dose group. A
high EC50 at the baseline in both the 800- and 1,800-mg treat-
ment groups was associated with a weaker antiviral response
(Fig. 2). Conversely, a low EC50 at the baseline was associated
with stronger antiviral response (Fig. 2). A similar relationship
TABLE 1. Baseline demographics and disease characteristics of the
patients in this study






Mean age, yr (SD) 41 (9) 40 (5) 39 (5)
No. (%) male 5 (83) 10 (83) 11 (92)
Race, n (%):
White 4 (67) 8 (67) 8 (67)
Black 2 (33) 4 (33) 2 (17)
Other 0 (0) 0 (0) 2 (17)
Mean wt, kg (SD) 80.9 (9.3) 75.4 (14.6) 81.5 (10.5)





















417 (268–548) 368 (233–808) 318 (155–901)
Mean PBA EC50,
ng/ml (SD)
48.5 (32.2)a 165.2 (211.8)b 1,041 (2,142)c
a n  4.
b n  11.
c n  11.
724 HANNA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
was observed regardless of whether antiviral activity was as-
sessed by the day 8 change in HIV-1 RNA or by the maximum
change in HIV-1 RNA.
No associations were noted between either the change on
day 8 or the maximum change in log10 HIV-1 RNA levels from
the baseline and the day 8 pharmacokinetic parameters AUC(TAU),
Cmax, Ctrough, and geometric mean Ctrough D6-8, which
were used as different measures of exposure to the study drug.
However, an association was observed between BMS-488043
levels adjusted by the baseline BMS-488043 susceptibility, as
estimated by EC50s and antiviral activity. A scatter plot of viral
load change from the baseline as a function of the ratio of
geometric mean Ctrough D6-8 to the baseline PBA EC50 is shown
in Fig. 3. The estimated correlation coefficient was numerically
higher when the change in plasma HIV-1 RNA from the base-
line was correlated with the ratio of drug exposure to the
baseline viral susceptibility (r  0.624) than with the baseline
viral susceptibility alone (r  0.519; comparison of Fig. 3 with
Fig. 2). Similar relationships were noted regardless of which
pharmacokinetic parameter [AUC(TAU), Cmax, Ctrough, or
Ctrough D6-8] was used as a measure of drug exposure.
In summary, a low antiviral response in any given subject was
predicted by a high baseline EC50 or a relatively low exposure
to the study drug.
Viral resistance to BMS-488043. The change in susceptibil-
ity of viral isolates to BMS-488043 over the 7.5 days of treat-
ment was measured as the ratio of the day 8 to the day 1
(predose) EC50. BMS-488043 susceptibility assays displayed a
variability of up to 10-fold when the same HIV-1 samples were
retested. Based on this observation, only 10-fold decreases in
BMS-488043 susceptibility were judged to represent con-
vincing changes in susceptibility related to selection of BMS-
488043 resistance. Consistent with this cutoff, HIV-1 from sub-
jects who received the placebo experienced an up-to-6.16-fold
decrease in BMS-488043 susceptibility.
Four subjects in the two dose groups developed resistance to
BMS-488043, with resistance associated with a 33- to 344-fold
decreased susceptibility by day 8. These subjects had a maximal
reduction in HIV-1 RNA of no more than 0.81 log10 copies/ml
(range, 0.38 to 0.81 log10 copies/ml), and their HIV-1 RNA
decreases from the baseline to day 8 ranged between 0 and 0.81
log10 copies/ml. The baseline PBA EC50s for these subjects
(21.96, 41.90, 61.67, and 87.86 ng/ml) were well within the
range of values observed for subjects who had a substantial
virological response (Fig. 3) and who did not develop markedly
decreased susceptibility to BMS-488043. Similarly, the ratio of
the geometric mean Ctrough D6-8 to the baseline PBA EC50 for
FIG. 1. Mean (standard error) changes in the log10 HIV-1 RNA level from the baseline following treatment with BMS-488043.
TABLE 2. Summary statistics for BMS-488043 pharmacokinetic parameters
Pharmacokinetic parameter
800 mg 1,800 mg
Day 1 (n  12) Day 8 (n  12) Day 1 (n  12) Day 8 (n  12)
Geometric mean Cmax, ng/ml (% CV) 2,353 (48.1) 2,833 (45.6) 3,712 (41.9) 4,109 (31.5)
Geometric mean AUC(TAU), ng  h/ml (% CV) 11,428 (54.2) 14,477 (39.6) 21,719 (33.2) 22,126 (31.9)
Geometric mean AI (% CV) 1.3 (100.7) 1.0 (27.4)
Median Tmax, h (range) 4 (2–12) 4 (3–6) 4 (3–8) 4 (3–6)
t1/2, h (SD) 15.0 (9.3) 17.7 (14.7)
Geometric mean Ctrough , ng/ml (% CV) 354.8 (60.0) 738.0 (79.9)
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these four subjects was well within the range observed for
subjects who did not develop resistance (data not shown).
Safety and tolerability. There were no SAEs or deaths fol-
lowing the administration of multiple oral doses of the study
medication, and no AE led to study discontinuation. Overall,
31 AEs were reported in 13 (43%) of 30 subjects, including 28
AEs in 11 (46%) of 24 subjects who received BMS-488043 and
3 AEs in 2 (33%) of 6 subjects who received the placebo. Most
of the reported AEs (28/31, 90%) were mild in intensity. The
remaining three AEs were considered moderate in intensity
and consisted of fatigue in a subject in the 800-mg group, an
abscess in a subject in the 800-mg group, and diarrhea in a
subject in the 1,800-mg group. The most common AE was
fatigue, reported by five (21%) of the BMS-488043-treated
subjects, all recipients of the 800-mg dose. There were no
abnormalities in vital signs, physical examination, clinical lab-
FIG. 2. Change in the log10 HIV-1 RNA level from the baseline at day 8 versus the baseline PBA EC50 with a fitted regression line. Fitted
regression line: change from the baseline HIV-1 RNA level in log10 at day 8  1.67484  0.17666 ln (baseline PBA EC50); 90% confidence
interval for slope, 0.04095 to 0.31237; P  0.0133; R2  0.2694; r  0.519. The value for one subject in the 800-mg BMS-488043 treatment arm
was excluded from the graph because the baseline EC50 was above the quantification limit (PBA EC50, 1,000,000 ng/ml). This subject experienced
a change in the HIV-1 RNA level of 0.32 log10 at day 8; however, this change was within the expected assay and biological variability of clinical
HIV-1 RNA measurements (3-fold or 0.5 log10). The values on the x axis are on a natural logarithm scale.
FIG. 3. Change in the log10 HIV-1 RNA level from the baseline at day 8 versus the ratio of the Ctrough D6-8 to the baseline PBA EC50 with a
fitted regression line. Fitted regression line: change from the baseline HIV-1 RNA level in log10 at day 8  0.50754 to 0.20065 ln (ratio of
CtroughD6-8 to the baseline PBA EC50); 90% confidence interval for slope, 0.31792 to 0.08338; P  0.0019; R
2  0.3891; r  0.624. The value
for one subject in the 800-mg BMS-488043 treatment arm was excluded from the graph (see legend to Fig. 2). The values on the x axis are on a
natural logarithm scale.
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oratory tests, or ECGs that were considered clinically signifi-
cant by the investigators.
DISCUSSION
BMS-488043 at a dose of 800 or 1,800 mg produced a re-
duction in plasma HIV-1 RNA from the baseline to day 8 of
greater than 0.7 log10 copies/ml, providing proof of concept for
this novel class of oral attachment inhibitors. Twice-daily ad-
ministration of 800- and 1,800-mg doses for 7.5 days was gen-
erally safe and well tolerated, suggesting promising safety and
tolerability of this class of antiretroviral agents. The pharma-
cokinetic results of this study indicate that the exposures to
BMS-488043 were dose related but less than dose propor-
tional, based on the 800- and 1,800-mg BMS-488043 doses
administered with a high-fat meal. There was no apparent drug
accumulation of the parent compound after twice-daily oral
dosing for 7.5 days. The lack of accumulation of BMS-488043
in this study is more consistent with the shorter t1/2 (11.1 h)
noted following the administration of BMS-488043 as an oral
solution (unpublished data) than the longer t1/2 (15 to 17.7 h)
reported in the present study. The t1/2 reported in this study is
most likely explained by absorption rate-limited pharmacoki-
netics as a result of the administration of BMS-488043 with a
high-fat meal.
Although BMS-488043 achieved 10-fold higher plasma drug
concentrations in humans than the prototype compound in this
series, BMS-378806 (10, 15), a major limitation of
BMS-488043 is its limited oral bioavailability. The requirement
of a high-fat meal in order to achieve these exposures suggests
that further optimization of this series of HIV-1 attachment
inhibitors is preferred. Although improvements in drug formu-
lation may have improved the bioavailability and mitigated
limiting food effects, development of this compound was ter-
minated to concentrate on newer-generation inhibitors. The
profile targeted included better intrinsic potency and more
favorable pharmacokinetic properties.
Of particular interest is the observed relationship between
viral susceptibility to BMS-488043 and in vivo antiviral activity.
This was evidenced by an association between a high mean
EC50 at the baseline in both the 800- and 1,800-mg treatment
groups and a weaker antiviral response. We were unable to
discern an association between several BMS-488043 pharma-
cokinetic parameters, when not adjusted by the baseline viral
drug susceptibility, and a virological response in this small
study. This is likely due in part to the very wide range (10,000-
fold) of individual variability in the BMS-488043 EC50, in con-
trast to the much narrower range of individual variability of
BMS-488043 pharmacokinetic parameters. The wide range of
individual variability in the EC50 is likely to have obscured a
relationship between drug exposure and virological response.
Notably, BMS-488043 levels adjusted by the baseline viral
BMS-488043 susceptibility were related to antiviral activity and
resulted in a numerically stronger association with virological
response than the baseline EC50 alone. This observation sug-
gests that both viral susceptibility and drug levels are important
determinants of viral response for this class.
Decreased susceptibility to BMS-488043 developed in four
subjects who received BMS-488043 and none of those who
received the placebo, providing further support of the direct
antiviral mechanism of BMS-488043. The antiviral activity of
BMS-488043 in these four subjects was modest. These subjects
had virus susceptible to BMS-488043 at the baseline that de-
veloped resistance during the course of the monotherapy ex-
posure. Resistance to BMS-488043 in cell culture has been
demonstrated and was associated with specific mutations in
gp120 (11). The underlying virological and/or biological mech-
anisms that allowed the rapid development of resistance in
the four subjects who developed drug resistance during BMS-
488043 administration in our study are being investigated.
However, the limited number of subjects precludes a robust
analysis of predictors of resistance selection in this small study.
These results suggest the need to decrease the intrinsic vari-
ability of antiviral activity of future attachment inhibitors in
this series while maintaining a favorable pharmacokinetic,
safety, and tolerability profile. Newer attachment inhibitors
with improved bioavailability and EC50s have been developed,
and one of them, BMS-663068, is currently in early clinical
development (ClinicalTrials.gov no. NCT01009814). Although
BMS-488043 is no longer in clinical development, its potent
anti-HIV activity, unique mode of action, and promising phar-
macokinetic and safety profile warrant further development of
this novel class of oral attachment inhibitors that target HIV-1
gp120 and prevent the binding of virus to CD4 lymphocytes
in HIV-1-infected persons.
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